RESEARCH
PUBLICATIONS
NEXTBIO COMMUNITY
Results presented below are derived from data collected from over 475 news feeds.
Click on one of these terms to refine your search
1 to 10 of 56 stories
-
Novartis's Tasigna More Effective Than Gleevec
The Wall Street Journal. - October 20, 2009Novartis's Tasigna works better than the company's own product Gleevec, a study showed, underpinning expectations that the new leukemia treatment will be able to make up for lost sales when the Swiss drug maker's second-best selling drug loses patent protection.
-
New understanding on Gleevec's limitations
News-Medical. - August 04, 2009University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.
-
Recently approved Gleevec drug for cancer treatment
News-Medical. - October 18, 2009Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual m…
-
Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec
News-Medical. - October 20, 2009Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-li…
-
A Conversation With Brian J. Druker, M.D.: Researcher Behind the Drug Gleevec
My Times. - November 02, 2009The oncologist recently was named a winner of this year s Lasker-DeBakey Clinical Medical Research Award.
-
Novartis New CML Drug Outperforms Glivec as First-Line Therapy for Ph+ Disease
Genetic Engineering & Biotechnology News. -
Finding key to cancer drug Gleevec's limitations
Science Centric. - August 06, 2009University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukaemia survive longer, but does not keep the disease from returning if treatment ends...
-
Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children
News-Medical. - October 07, 2009Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of…
-
CLINICAL IMPLICATIONS OF BASIC RESEARCH: Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity
NEJM.Tyrosine kinases are major targets of contemporary chemotherapy, and tyrosine kinase inhibitors — such as imatinib mesylate (Gleevec, Novartis; formerly known as STI571) — are approved for the treatment of...
-
Predicting patient response to gleevec in gastrointestinal stromal tumours
Science Centric. - April 22, 2009Researchers at Fox Chase Cancer Centre uncovered a genetic pattern that may help predict how gastrointestinal stromal tumour (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make t…
